SEATTLE, Oct. 9, 2024 /PRNewswire/ -- Arbele, a leading innovator in biopharmaceutical & biotechnology focused on targeting cadherin-17 (CDH17), is pleased to announce strategic collaborations in precision oncology using artificial intelligence (AI) to advance targeted immunotherapeutics of bispecific T-cell engagers (TCEs) and antibody-drug conjugates (ADCs). These partnerships, aimed at advancing the quantification and prognostic prediction of CDH17 expression in tumor tissue and the surrounding tumor immune microenvironment, are expected to accelerate the development of precise companion diagnostics and effective clinical trials for the treatment of advanced cancer patients.

Join us at ESMO - European Society for Medical Oncology where we share our work on companion diagnostics for cabotamig in GI cancers. We are working towards establishing the GOLD standard in CDH17 diagnostics.

Arbele, a biotechnology company dedicated to fighting gastrointestinal cancers, celebrates its 7th anniversary and the opening of Tiberias Technology (TibTech), its accredited lab for cancer screening and in vitro diagnostics, at the Hong Kong Science and Technology Park.